Mr. Carlos Ponce reports

LUMIERA HEALTH SIGNS DISTRIBUTION AGREEMENT TO LAUNCH AWAYE IN VIETNAM - A MARKET OF 100 MILLION PEOPLE

Lumiera Health Inc. has signed a distribution agreement with Fideschem International Ltd., a Singapore-based company, that will enable Awaye to access the Vietnamese market, which has a population of approximately 100 million people and a pain relief market forecasted to grow at greater than 11.24 per cent annually for the foreseeable future.

"In addition to our recent announcements that the U.S. Food & Drug Administration (FDA) has published final registration of the company's national drug code (NDC) allowing Awaye to be sold as an OTC drug across the U.S., a market of approximately 330 million people with a pain relief category of $6-billion (U.S.), we are working to further expand the market potential for Awaye. We are very pleased to be working with the Fideschem team in the Vietnamese market which is a market of approximately 100 million people. Based on the market dynamics, and the trend to more natural health products and natural pain relief products, the Fideschem team has forecasted tremendous success for Awaye," says Carlos Ponce, chief executive officer of Lumiera Health.

"We strongly believe that Awaye has the potential to capture significant market share in Vietnam. Awaye is perfectly positioned to leverage the growing demand for natural, non-addictive pain management solutions combined with consumer trust towards Canadian products," says Nguyen Minh Hieu, managing director at Fideschem International.

As a part of the agreement, Fideschem will first obtain and maintain all regulatory requirements to allow the sales of Awaye in Vietman, and then manage all sales and marketing initiatives. Based on the regulatory process to commercialize health products in Vietnam, Fideschem and Lumeira forecast sales to begin in 12 months.

"Awaye truly is a great product that naturally helps people manage their pain, and we continue to receive positive feedback from people that are trying and buying Awaye. With confidence and conviction in our product, we are executing our accelerated growth plans. We are still very early in our execution; we launched Awaye in April, 2021, and we are seeing tremendous growth with limited distribution. We are focused on increasing market access, then building distribution and trial. In 12 months, with the launch in Vietnam in addition to our distribution focus in Canada and the U.S., Awaye will be available to more the 465 million people. We look forward to continuing to expand distribution and to accelerate the number of people that try and buy Awaye within our rapidly growing market potential," says Carlos Ponce, chief executive officer of Lumiera.

About Awaye

Awaye provides a new generation of relief from acute and chronic pain by exploiting the CB2 receptors of the endocannabinoid system, the body's built-in pain and inflammation defence system. Awaye is a unique Health Canada approved topical cream that provides relief from pain through complimentary mechanisms of action not found in any other product currently available on the market.

About Lumiera Health Inc.

Lumiera specializes in the development and commercialization of consumer products for the natural health industry. The company sells herbal tonics and natural supplements through its Holizen Laboratories division, with a diverse portfolio including a line of innovative sleep aids. The company is also commercializing a unique topical product line acting on the endocannabinoid system, without the use of cannabis, that provides an innovative solution for chronic pain and inflammation. A pioneer in the natural health innovation space, the Lumiera brand is rooted in the core values of science, nature and compassion. The company's goal is to make people's lives better by developing natural health and wellness products that are effective, safe and trustworthy.

We seek Safe Harbor.